Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart

Acta Pharmacologica Sinica

Volumn 25, Issue 11, 2004, Pages 1444-1449

  Li, Ling ^a   Yuan, Wen Jun ^a   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Coronary circulation; Heart function tests; Nitric oxide; Nitric oxide synthase; Rats; Urotensin II

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; UROTENSIN II;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD FLOW VELOCITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FUNCTION; HEART MUSCLE; ISOLATED HEART; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TIME; WESTERN BLOTTING;

ANIMALS; CORONARY CIRCULATION; HEART FUNCTION TESTS; MALE; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; UROTENSINS;

EID: 8544270105     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neuro-secretory system. I: "Urophysiology" and the caudal neurosecretory system of fishes. Rec Prog Horm Res 1985; 41: 533-52.
2. Conlon JM, Yano K, Waugh D, Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Expl Zool 1996; 275: 226-38.
3. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998; 15: 803-8.
4. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999; 457: 28-32.
5. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trend Cardiovasc Med 2000; 10: 229-37.
6. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 1995; 209: 752-9.
7. Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, et al. Cloning and chromosomal mapping of three novel genes: GPR9, GPR10, and GPR14, encoding receptors related to interleukin δ, neuropeptide Y, and somatostatin receptor. Genomic 1995; 29: 335-44.
8. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-6.
9. Liu QY, Pong SS, Zeng ZZ. Identification of urotensin II as the endogenous ligand for the orphan G-protein-couple receptor GPR14. Biochem Biophys Res Commun 1999; 266: 174-8.
10. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor. SENR (GPR14). Biochem Biophys Res Commun 1999; 265: 123-9.
11. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999; 1: 383-5.
12. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810-1.
13. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001; 132: 5-9.
14. Abdelrahman AM, Pang CC. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002; 71: 819-25.
15. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000; 130: 201-4.
16. Gibson A, Wallace P, Bern HA. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol 1986; 64: 435-9.
17. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 2000; 402: R5-7.
18. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001; 69: 175-80.
19. Kelly R, Balligand J, Smith T. Nitric oxide and cardiac function. Circ Res 1996; 79: 363-80.
20. Seki T, Hagiwara H, Naruse K, Kadowaki M, Kashiwagi M, Demura H, et al. In situ identification of messenger RNA of endothelial type nitric oxide synthase in rat cardiomyocytes. Biochem Biophys Res Commun 1996; 218: 601-5.
21. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 239: 2002-12.
22. ca-1 is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 6510-5.
23. Nelissen-Vrancken HJ, Debets JJ, Snoeckx LH, Daemen MJ, Smits JF. Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation 1996; 93: 349-55.
24. Wei C, Jiang S, Lust J, Daly R, MacGregor C. Genetic expression of endothelial nitric oxide synthase in human atrial myocardium. Mayo Clin Proc 1996; 71: 346-50.
25. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997; 17: 1846-58.
26. Hannan RL, Jone MC, Kouretas PC, Hack BD, Matherne GP, Laubach VE. Deletion of endothelial nitric oxide synthase exacerbates myocardial stuning in an isolated mouse heart model. J Surg Res 2000; 93: 127-32.